There are 2789 resources available
747P - Real-world experience of rucaparib in patients with ovarian cancer: A multicentre United Kingdom study
Presenter: Mark Lythgoe
Session: ePoster Display
748P - Real-world-data (RWD) on platinum (Pt)-based chemotherapy (CT) after PARP inhibitors (PARPi) in high-grade serous (or endometrioid) ovarian cancer (HGSEOC)
Presenter: Margarita Romeo Marin
Session: ePoster Display
749P - Cardiotoxicity in patients treated with PARP-inhibitors
Presenter: Mariola Blanco Clemente
Session: ePoster Display
750P - Safety and efficacy of platinum desensitization treatment in patients with ovarian cancer and platinum hypersensitivity
Presenter: Simona Manacorda
Session: ePoster Display
751P - Survival prognostic and surrogate values of the early modeled CA-125 KELIM in newly diagnosed advanced ovarian cancer: Data from the GCIG meta-analysis group
Presenter: Pauline Corbaux
Session: ePoster Display
752P - PARP-inhibitors beyond progression: A new way to manage oligometastatic ovarian cancer recurrence
Presenter: Eleonora Palluzzi
Session: ePoster Display
753P - Adverse events experienced by patients in the placebo arm of maintenance therapy trials in advanced ovarian cancer
Presenter: Sandy Simon
Session: ePoster Display
920P - The sarcopenia skeletal muscle mass index (SMI) has a three-tier survival effect in HNSCC, which can be predicted by hemoglobin (Hb), lymphocytes (Ly) and creatinine (Cre)
Presenter: Simona Guerriero
Session: ePoster Display
921P - Assessment of health-related quality of life in head and neck cancer patients treated with chemoradiation
Presenter: VINAYAKUMAR MUTTAGI
Session: ePoster Display
922P - Efficacy of immunotherapy (IO) and subsequent systemic treatment after failure of IO in patients with recurrent or metastatic head and neck cancer in a real-world setting
Presenter: Michael Pogorzelski
Session: ePoster Display